Healthcare professionals
On this page, you will find information on the Agency’s activities that are most relevant to healthcare professionals, including news, and events. You can contribute to the Agency’s work by responding to public consultations. Learn more about how Healthcare Professionals are actively involved in the work of the Agency.
Featured information
-
List item
Public consultation on draft framework for paediatric clinical trial preparedness
The European Network of Paediatric Research at the European Medicines Agency invites all stakeholders involved in paediatric clinical trials to provide comments on its draft framework on paediatric clinical trial preparedness by writing to enpremasurveys@ema.europa.eu, by 15 November 2019. The aim of this consultation is to identify potential gaps and present a more comprehensive view.
-
List item
Collaboration with general practitioners
EMA and the two major organisations representing general practitioners (GPs) and family physicians in Europe have signed a joint statement committing to strengthening interactions. It contains an action plan until 2020, which includes involving GPs and family physicians in EMA evaluations, developing relevant communication activities and exploring further collaboration with research networks in primary care, with a focus on generating real-world evidence. It also identifies opportunities for cooperation in regulatory science training.
-
List item
Preventing Brexit-related medicine shortages
EMA has published a questions-and-answers document to address potential questions from stakeholders on the supply of medicines in the EU after Brexit and what the Agency, the European Commission and national competent authorities in the Member States are doing to prevent potential medicine supply shortages due to Brexit.
-
List item
The journey of a centrally authorised medicine
EMA's new booklet describes the journey of a medicine for human use authorised via EMA, from initial research to discussions on patient access to medicines across the EU. This includes how EMA supports medicine development by providing scientific advice and how it assesses a medicine’s benefits and risks once it receives an application for marketing authorisation.
-
List item
Electronic product information
The European Commission, the Heads of Medicines Agencies and EMA are working together to facilitate the development of electronic tools to improve access of patients and healthcare professionals to product information in the EU. Following a stakeholder workshop, they launched a public consultation until 31 July 2019 on draft key principles to form the basis on which electronic product information (ePI) for human medicines will be developed and used in the EU.
-
List item
Workshop on availability of authorised medicines
At a multi-stakeholder workshop in December 2018, representatives of patients, consumers, healthcare professionals and pharmaceutical industry stakeholders joined regulators to discuss the work of the Heads of Medicines Agencies/EMA task force on the availability of medicines and how to contribute to its deliverables. The task force was set up to provide strategic support and advice to tackle disruptions in supply of human and veterinary medicines and ensure their continued availability.
